Tomoko Hamaya

Disclosure information not submitted.

Presentation(s):

• PD58-12: Cross-reactivity between the first-line chemotherapy and subsequent immunotherapy in patients with unresectable or metastatic urothelial carcinoma

  Monday, May 16, 2022
  2:50 PM – 3:00 PM